Immunocore Holdings (IMCR) Change in Account Payables (2021 - 2026)

Immunocore Holdings (IMCR) has reported Change in Account Payables for 6 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Account Payables rose 78.76% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $176000.0 (down 98.64% YoY) and the FY2025 annual result came in at -$2.5 million, down 133.77% from the prior year.
• Change in Account Payables improved to $6.0 million in Q1 2026 per IMCR's latest filing, from $1.4 million in the prior quarter.
• Over the last five years, Change in Account Payables for IMCR reached as high as $18.9 million in Q3 2022 and fell as low as -$6.9 million in Q2 2025.
• A 5-year average of $3.0 million and a median of $3.3 million in 2025 frame the typical range for Change in Account Payables.
• The largest YoY upside for Change in Account Payables was 244.05% in 2025 against a maximum downside of 254.53% in 2025.
• Year by year, Change in Account Payables stood at $13.2 million in 2022, then sank by 71.53% to $3.8 million in 2023, then surged by 56.7% to $5.9 million in 2024, then plunged by 75.9% to $1.4 million in 2025, then surged by 321.3% to $6.0 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $6.0 million, $1.4 million, and -$287000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.